TPO and autoimmune thrombocytopenic purpura: The findings presented in this manuscript not only are relevant for enhancing the efficacy of in vitro platelet production but also may open avenues for therapeutic options to treat thrombocytopenic patients with reduced proplatelet formation capacity despite normal or high MK counts as observed in ITP patients undergoing treatment with TPO mimetics such as eltrombopag or romiplostim (78).